News

These two pivotal Phase 3 trials of long-acting subcutaneous buprenorphine injections, CAM2038, in patients with opioid dependence were designed to establish clinical efficacy and long-term safety of both

The decision comes two days after the US Treasury announced additional action to curb inversions, and address earnings stripping. The US Department of the Treasury and the Internal

Sareum plans to start clinical trials in second quarter of this year, subject to final NHS approval. The company plans to carry out two phase I clinical trials

Inflectra is indicated to treat patients with various severe autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The FDA

Based on the DSMB’s recommendation, enrollment in the trial will continue as planned. The HOPE-Duchenne trial is evaluating CAP-1002, Capricor’s lead product candidate, in boys with Duchenne muscular

Pursuant to the acquisition, Citius acquired all of the outstanding shares of LMB common stock in exchange for shares of Citius common stock. LMB is a private, late-stage

The compound, SEP-856, is a potential antipsychotic agent with a novel mechanism of action being investigated as a possible treatment for patients with schizophrenia. The preclinical models for

Accelerated review status enables CHMP to grant an opinion two months earlier than the standard 210-day period. In XBiotech’s case, a decision may happen as early as third

Nimbus will get $400m up front and up to $800m if certain development milestones are reached. The Nimbus Apollo program includes lead candidate NDI-010976 and other preclinical ACC